These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11695333)

  • 1. Monitoring anti-HIV medicines: what is the FDA's role?
    Mirken B
    BETA; 2001; 14(1):8-11. PubMed ID: 11695333
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA notifications. FDA grants approval for raltegravir.
    AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
    [No Abstract]   [Full Text] [Related]  

  • 3. Not enough warning. GAO report finds FDA's medical device monitoring lacking.
    Hensley S
    Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267
    [No Abstract]   [Full Text] [Related]  

  • 4. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir's trials and tribulations.
    Gilden D
    GMHC Treat Issues; 1998 Nov; 12(11):1-3. PubMed ID: 11365905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA panel fails to recommend adefovir approval. Food and Drug Administration.
    Highleyman L
    BETA; 1999; 12(4):4. PubMed ID: 11367249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FDA's poor oversight of postmarketing studies.
    Lancet; 2009 Nov; 374(9701):1568. PubMed ID: 19897111
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 10. StatBite. FDA-required postmarketing studies, 1992-2008.
    J Natl Cancer Inst; 2010 Sep; 102(17):1303. PubMed ID: 20739654
    [No Abstract]   [Full Text] [Related]  

  • 11. First fusion inhibitor for advanced HIV.
    Am J Nurs; 2003 Jul; 103(7):64F. PubMed ID: 12877130
    [No Abstract]   [Full Text] [Related]  

  • 12. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 13. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

  • 14. Viread gets FDA nod.
    Rodriquez E
    Posit Living; 2001 Dec-2002 Jan; 10(7):33. PubMed ID: 11808509
    [No Abstract]   [Full Text] [Related]  

  • 15. On approval.
    Huff B
    GMHC Treat Issues; 2001 Oct; 15(10):5-8. PubMed ID: 11727570
    [No Abstract]   [Full Text] [Related]  

  • 16. Maraviroc--new HIV drug. Emerging options need to be used wisely.
    Vázquez E
    Posit Aware; 2007; 18(4):18-9. PubMed ID: 17682275
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA notifications. Reyataz is approved for HIV treatment.
    AIDS Alert; 2003 Sep; 18(9):119-20. PubMed ID: 14686309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does $760 m a year of industry funding affect the FDA's drug approval process?
    Wolfe SM
    BMJ; 2014 Aug; 349():g5012. PubMed ID: 25096994
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA approval of nevirapine for HIV.
    Am Fam Physician; 1996 Oct; 54(5):1805-6. PubMed ID: 8857799
    [No Abstract]   [Full Text] [Related]  

  • 20. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.